Global Retirement Partners LLC Acquires 194 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Global Retirement Partners LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,982 shares of the biopharmaceutical company’s stock after purchasing an additional 194 shares during the period. Global Retirement Partners LLC’s holdings in Gilead Sciences were worth $830,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bellevue Group AG boosted its stake in shares of Gilead Sciences by 18.2% during the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock valued at $3,859,000 after purchasing an additional 7,093 shares in the last quarter. Quantinno Capital Management LP boosted its stake in shares of Gilead Sciences by 149.5% during the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock valued at $6,843,000 after purchasing an additional 48,910 shares in the last quarter. McAdam LLC boosted its stake in shares of Gilead Sciences by 16.7% during the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company’s stock valued at $2,344,000 after purchasing an additional 3,627 shares in the last quarter. IRON Financial LLC bought a new position in shares of Gilead Sciences during the third quarter valued at approximately $830,000. Finally, Capital Investment Advisors LLC boosted its stake in shares of Gilead Sciences by 2.6% during the fourth quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock valued at $35,793,000 after purchasing an additional 9,791 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the sale, the director now owns 8,920 shares in the company, valued at $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now owns 80,801 shares in the company, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 713,000 shares of company stock valued at $67,945,181. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on GILD shares. The Goldman Sachs Group raised their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Citigroup started coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They issued a “buy” rating and a $125.00 target price for the company. Robert W. Baird raised their target price on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Finally, Oppenheimer raised their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $102.08.

Gilead Sciences Trading Down 0.1 %

Shares of Gilead Sciences stock opened at $109.95 on Friday. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $111.03. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The firm has a fifty day moving average price of $95.41 and a 200 day moving average price of $88.73. The stock has a market cap of $137.03 billion, a PE ratio of 297.16, a price-to-earnings-growth ratio of 0.71 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a $0.79 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.87%. Gilead Sciences’s payout ratio is presently 832.43%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.